晚上户外照明和痴呆症中神经精神症状
Manuela Tondelli1,2, Tommaso Filippini3,4,5, Giulia Vinceti6
1Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. manuela.tondelli@unimore.it.
GeroScience
|July 14, 2025
概括
夜间人工光 (LAN) 暴露与痴呆症患者的神经精神病症状增加有关,特别是精神病和睡眠问题. 这表明LAN可能是一个环境风险因素,影响该人口的心理健康.
科学领域:
- 环境健康 环境健康
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
背景情况:
- 越来越多的人对夜间人工光线 (LAN) 和心理健康感兴趣.
- 关于LAN对痴呆症患者的影响的研究有限.
- 需要探索痴呆症神经精神病症状的环境风险因素.
研究的目的:
- 调查LAN暴露与痴呆症患者的神经精神症状之间的关联.
- 确定LAN是否是这些症状的潜在环境风险因素.
- 分析受LAN暴露影响的特定症状领域.
主要方法:
- 该研究包括150名意大利莫德纳的痴呆症患者.
- 使用卫星图像评估的LAN暴露.
- 使用神经精神病学目录 (NPI) 评估的神经精神病学症状.
- 用于检查关联的物流回归模型.
主要成果:
- 较高的LAN暴露与精神症状的风险增加相关.
- 与精神病 (妄想,幻觉) 和睡眠障碍发现了重要的关联.
- 超过中位数LAN暴露的个体表现出这些症状的风险增加 (OR=2.09).
- 对于冷漠和情感障碍,观察到较弱的关联.
结论:
- 人工夜间照明暴露可能会对痴呆症患者的心理健康产生负面影响.
- 暴露于LAN可能会加剧精神病症状和睡眠障碍.
- 需要对更大的样本进行进一步的研究,以证实研究结果并解决混因素.
相关概念视频
Photoreceptors and Visual Pathways
6.5K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.5K
Negative and Cognitive Symptoms of Schizophrenia
125
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
125
Substance Use Disorders Affecting Sleep
223
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
223
Insufficient Sleep and Sleep Deprivation
222
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
222
Dementia
169
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
169
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263


